Educational Objectives At the conclusion of this activity, participants should be able to demonstrate the ability to: • Examine the extent of residual CVD risk that continues to burden dyslipidemic ACS patients despite intensive statin treatment • Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk • Explain the rationale for developing CETP modulators and inhibitors to increase HDL and reduce CVD risk • Discuss how the modulation of complex cholesterol metabolism could have an impact on atherogenesis and improve clinical outcomes